Icad Return on Average Equity from 2010 to 2024

ICAD Stock  USD 1.42  0.03  2.07%   
Check Icad financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Icad's main balance sheet or income statement drivers, such as Depreciation And Amortization of 388.6 K, Interest Expense of 15.2 K or Total Revenue of 23.3 M, as well as many indicators such as Price To Sales Ratio of 5.08, Dividend Yield of 0.0 or PTB Ratio of 1.29. Icad financial statements analysis is a perfect complement when working with Icad Valuation or Volatility modules.
  
Check out the analysis of Icad Correlation against competitors.

About Icad Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Icad income statement, its balance sheet, and the statement of cash flows. Icad investors use historical funamental indicators, such as Icad's Return on Average Equity, to determine how well the company is positioned to perform in the future. Although Icad investors may use each financial statement separately, they are all related. The changes in Icad's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Icad's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Icad Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Icad. Please read more on our technical analysis and fundamental analysis pages.
iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the treatment of cancer in the United States. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire. Icad operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 136 people.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Information and Resources on Investing in Icad Stock

When determining whether icad inc is a strong investment it is important to analyze Icad's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Icad's future performance. For an informed investment choice regarding Icad Stock, refer to the following important reports:
Check out the analysis of Icad Correlation against competitors.
You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Health Care Technology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Icad. If investors know Icad will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Icad listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.20)
Revenue Per Share
0.693
Quarterly Revenue Growth
0.143
Return On Assets
(0.08)
Return On Equity
(0.16)
The market value of icad inc is measured differently than its book value, which is the value of Icad that is recorded on the company's balance sheet. Investors also form their own opinion of Icad's value that differs from its market value or its book value, called intrinsic value, which is Icad's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Icad's market value can be influenced by many factors that don't directly affect Icad's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Icad's value and its price as these two are different measures arrived at by different means. Investors typically determine if Icad is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Icad's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.